Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.

A multicenter study led by Vanderbilt University Medical Center (VUMC) investigators found that pancreatic cancer patients who underwent surgery and received chemotherapy lived longer and had fewer cancer recurrences in other parts of the body than patients who also received chemoradiation therapy.

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients.

Investigators at Vanderbilt University Medical Center have published research regarding an important feature of colorectal cancer (CRC) that could eventually lead to the development of non-invasive means of monitoring cancer progression. After lung cancer, CRC is the second-most lethal cancer in the United States.

Lindsay Ramsey Smith, MSN, R.N., a quality consultant for the Vanderbilt Transplant Center (VTC), recently uncovered some interesting data that sparked a center-wide improvement project.

Pink will be the dominant color in Memorial Gymnasium Sunday, Feb. 14, as the Vanderbilt Commodores Women’s Basketball team participates in the annual Pink Out! game to raise awareness about breast cancer.